Advanced

FARMAKOKINETIČKO MODELOVANJE VALPROATA KOD PACIJENATA SA EPILEPSIJOM

Jakovljević, Mihajlo B LU ; Janković, Slobodan M; Todorović, Natalija; Milovanović, Jasmina R and Janković, Snezana (2010) In Medicinski pregled 63(5-6). p.55-349
Abstract

INTRODUCTION: The aim of our study was to develop and use a population pharmacokinetic model for assessment of individual valproate clearance in children and young adults suffering from epilepsy.

MATERIAL AND METHODS: The analysis was performed using 52 steady-state concentrations of valproate collected from 26 epileptic patients during the routine clinical practice in our hospital. The mean values of age and total body weight were 19.92 years and 57.12 kg, respectively. NONMEM software with ADVAN 1 subroutine was used for model building and assessing the influence of different covariates. A validation set of 20 epileptic patients (one blood sample per a patient) was used to estimate predicted performances of the pharmacokinetic... (More)

INTRODUCTION: The aim of our study was to develop and use a population pharmacokinetic model for assessment of individual valproate clearance in children and young adults suffering from epilepsy.

MATERIAL AND METHODS: The analysis was performed using 52 steady-state concentrations of valproate collected from 26 epileptic patients during the routine clinical practice in our hospital. The mean values of age and total body weight were 19.92 years and 57.12 kg, respectively. NONMEM software with ADVAN 1 subroutine was used for model building and assessing the influence of different covariates. A validation set of 20 epileptic patients (one blood sample per a patient) was used to estimate predicted performances of the pharmacokinetic model.

RESULTS: The typical mean value of the clearance of valproate estimated by the base model in our population was 0.3 77 I/h. Out of five considered covariates (total body weight, age, total daily dose, gender and polytherapy) only the age of the patients was a significant determinant of the clearance of valproate. The final regression model for the clearance of valproate was as following: CL (l/h) = 0.223 + 0.00819 * AGE CONCLUSION: The derived pharmacokinetical model describes the clearance of valproate in relation to patient's age in the observed population. it will help to improve the seizure control in young patients with epilepsy in Serbian population.

(Less)
Please use this url to cite or link to this publication:
author
alternative title
Pharmacokinetic modelling of valproate in epileptic patients
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adolescent, Adult, Anticonvulsants/pharmacokinetics, Child, Epilepsy/drug therapy, Female, Humans, Male, Valproic Acid/pharmacokinetics, Young Adult
in
Medicinski pregled
volume
63
issue
5-6
pages
7 pages
publisher
Drustvo Lekara Vojvodine
external identifiers
  • scopus:79952197411
ISSN
0025-8105
DOI
10.2298/MPNS1006349J
language
Serbian
LU publication?
no
id
be130309-5102-4f2d-92b9-daf154612595
date added to LUP
2018-09-01 23:09:15
date last changed
2019-08-06 03:03:55
@article{be130309-5102-4f2d-92b9-daf154612595,
  abstract     = {<p>INTRODUCTION: The aim of our study was to develop and use a population pharmacokinetic model for assessment of individual valproate clearance in children and young adults suffering from epilepsy.</p><p>MATERIAL AND METHODS: The analysis was performed using 52 steady-state concentrations of valproate collected from 26 epileptic patients during the routine clinical practice in our hospital. The mean values of age and total body weight were 19.92 years and 57.12 kg, respectively. NONMEM software with ADVAN 1 subroutine was used for model building and assessing the influence of different covariates. A validation set of 20 epileptic patients (one blood sample per a patient) was used to estimate predicted performances of the pharmacokinetic model.</p><p>RESULTS: The typical mean value of the clearance of valproate estimated by the base model in our population was 0.3 77 I/h. Out of five considered covariates (total body weight, age, total daily dose, gender and polytherapy) only the age of the patients was a significant determinant of the clearance of valproate. The final regression model for the clearance of valproate was as following: CL (l/h) = 0.223 + 0.00819 * AGE CONCLUSION: The derived pharmacokinetical model describes the clearance of valproate in relation to patient's age in the observed population. it will help to improve the seizure control in young patients with epilepsy in Serbian population.</p>},
  author       = {Jakovljević, Mihajlo B and Janković, Slobodan M and Todorović, Natalija and Milovanović, Jasmina R and Janković, Snezana},
  issn         = {0025-8105},
  keyword      = {Adolescent,Adult,Anticonvulsants/pharmacokinetics,Child,Epilepsy/drug therapy,Female,Humans,Male,Valproic Acid/pharmacokinetics,Young Adult},
  month        = {12},
  number       = {5-6},
  pages        = {55--349},
  publisher    = {Drustvo Lekara Vojvodine},
  series       = {Medicinski pregled},
  title        = {FARMAKOKINETIČKO MODELOVANJE VALPROATA KOD PACIJENATA SA EPILEPSIJOM},
  url          = {http://dx.doi.org/10.2298/MPNS1006349J},
  volume       = {63},
  year         = {2010},
}